Nabiel A Mir1, Olivia Hull1, Sheneka Bothwell1, Devika Das1. 1. is a Clinical Nurse Educator, and is the Section Chief of Oncology, both at Birmingham Veterans Affairs Medical Center in Alabama. was an Internal Medicine Resident in the Department of Medicine at the time the article was written; is a Fellow in the Division of Hematology and Oncology, and Devika Das is Clinical Assistant Professor of Hematology and Oncology, all at University of Alabama at Birmingham.
Abstract
BACKGROUND: Durvalumab is recommended by national guidelines for patients with unresectable stage III non-small cell lung cancer (NSCLC) following concurrent chemoradiation therapy (CRT). Nonadherence to guidelines is associated with adverse outcomes. We studied the adherence and identified barriers to durvalumab usage at the Birmingham Veterans Affairs Medical Center (VAMC) Oncology Clinic in Alabama. METHODS: Using retrospective analysis, we assessed the use of consolidative durvalumab among veterans at Birmingham VAMC. The health records of all veterans with stage III unresectable NSCLC from October 2017 to August 2019 were reviewed. Data collected included demographics, barriers to CRT initiation and completion, durvalumab usage, and reasons for not prescribing durvalumab. RESULTS: In our data review, 34 patients were found to have stage III unresectable NSCLC. Twenty (58.8%) of those 34 initiated CRT, but only 16 (47.1%) completed CRT treatment and 7 (20.6%) underwent further treatment with durvalumab. Of the 14 patients who did not initiate CRT, the most common reasons were poor performance status and/or the presence of comorbidities. Of the evaluable cohort of 34, 11 (32.4%) patients with stage III NSCLC received durvalumab. Of the 9 eligible patients who did not receive durvalumab, the most common reasons cited were toxicities experienced during or following CRT (11.8%). CONCLUSIONS: Just one-third of patients were eligible to receive durvalumab at Birmingham VAMC. This was likely due to the difference between clinical trial and real-world patient populations. Interventions to address socioeconomic and system level barriers to improve our center's delivery of lung cancer treatment are planned.
BACKGROUND: Durvalumab is recommended by national guidelines for patients with unresectable stage III non-small cell lung cancer (NSCLC) following concurrent chemoradiation therapy (CRT). Nonadherence to guidelines is associated with adverse outcomes. We studied the adherence and identified barriers to durvalumab usage at the Birmingham Veterans Affairs Medical Center (VAMC) Oncology Clinic in Alabama. METHODS: Using retrospective analysis, we assessed the use of consolidative durvalumab among veterans at Birmingham VAMC. The health records of all veterans with stage III unresectable NSCLC from October 2017 to August 2019 were reviewed. Data collected included demographics, barriers to CRT initiation and completion, durvalumab usage, and reasons for not prescribing durvalumab. RESULTS: In our data review, 34 patients were found to have stage III unresectable NSCLC. Twenty (58.8%) of those 34 initiated CRT, but only 16 (47.1%) completed CRT treatment and 7 (20.6%) underwent further treatment with durvalumab. Of the 14 patients who did not initiate CRT, the most common reasons were poor performance status and/or the presence of comorbidities. Of the evaluable cohort of 34, 11 (32.4%) patients with stage III NSCLC received durvalumab. Of the 9 eligible patients who did not receive durvalumab, the most common reasons cited were toxicities experienced during or following CRT (11.8%). CONCLUSIONS: Just one-third of patients were eligible to receive durvalumab at Birmingham VAMC. This was likely due to the difference between clinical trial and real-world patient populations. Interventions to address socioeconomic and system level barriers to improve our center's delivery of lung cancer treatment are planned.
Authors: Louis P Garrison; Peter J Neumann; Pennifer Erickson; Deborah Marshall; C Daniel Mullins Journal: Value Health Date: 2007 Sep-Oct Impact factor: 5.725
Authors: Robert E Bristow; Jenny Chang; Argyrios Ziogas; Belinda Campos; Leo R Chavez; Hoda Anton-Culver Journal: J Am Coll Surg Date: 2015-02-14 Impact factor: 6.113
Authors: Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takayasu Kurata; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Corinne Faivre-Finn; Martin Reck; Johan Vansteenkiste; David R Spigel; Catherine Wadsworth; Giovanni Melillo; Maria Taboada; Phillip A Dennis; Mustafa Özgüroğlu Journal: N Engl J Med Date: 2018-09-25 Impact factor: 91.245
Authors: Karlijn J G Schulkes; Cindy Nguyen; Frederiek van den Bos; Leontine J R van Elden; Marije E Hamaker Journal: Lung Date: 2016-09-20 Impact factor: 2.584
Authors: F Andrew Kozel; Nyaz Didehbani; Bambi DeLaRosa; Christina Bass; Caitlin D Schraufnagel; Cassie Rae Morgan; Penelope Jones; Jeffrey S Spence; John Hart Journal: J Neuropsychiatry Clin Neurosci Date: 2015-12-16 Impact factor: 2.198
Authors: Abdulrahman Jazieh; Mohammad Omar Alkaiyat; Yosra Ali; Mohamed Ahmed Hashim; Nafisa Abdelhafiz; Ashwaq Al Olayan Journal: BMJ Open Qual Date: 2019-08-26